Thrombosis in End‐Stage Renal Disease (Q33348067)

26 July 2017

1 reference

title

Thrombosis in end-stage renal disease (English)

1 reference

26 July 2017

Thrombosis in End‐Stage Renal Disease (English)

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

3 January 2024

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

3 January 2024

author name string

Liam F. Casserly

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12753687

3 January 2024

Laura M. Dember

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12753687

3 January 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12753687

3 January 2024

publication date

1 May 2003

1 reference

full work available at URL

26 July 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1525-139X.2003.16048.x

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1525-139X.2003.16048.x

3 January 2024

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

https://onlinelibrary.wiley.com/doi/full-xml/10.1046/j.1525-139X.2003.16048.x

3 January 2024

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

3 January 2024

1 reference

26 July 2017

16

1 reference

26 July 2017

245-256

1 reference

26 July 2017

3

1 reference

Extrarenal complications of the nephrotic syndrome

26 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2003.16048.X

Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2003.16048.X

Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2003.16048.X

Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2003.16048.X

Protein S deficiency and skin necrosis associated with continuous ambulatory peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2003.16048.X

Recombinant human erythropoietin to correct uremic bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2003.16048.X

Coagulation Studies and Fistula Blood Flow During Erythropoietin Therapy in Haemodialysis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2003.16048.X

Acute renal allograft dysfunction in the setting of deep venous thrombosis: a case of successful urokinase thrombolysis and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2003.16048.X

Detection and treatment of dysfunctional hemodialysis access grafts: effect of a surveillance program on graft patency and the incidence of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2003.16048.X

Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2003.16048.X

Blood coagulation in renal failure

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Hypercoagulopathy in a hemodialysis patient: are elevations in factors VII and VIII effective?

3 January 2024

2

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Thrombosis and hemostasis in renal disease

3 January 2024

3

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Thromboembolic risks and complications in nephrotic children

3 January 2024

4

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome

3 January 2024

5

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Evidence against a platelet cyclooxygenase defect in uraemic subjects on chronic haemodialysis

3 January 2024

7

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis

3 January 2024

8

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase

3 January 2024

9

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect

3 January 2024

10

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Studies of the platelet fibrinogen receptor in Glanzmann patients and uremic patients

3 January 2024

13

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Expression of fibrinogen receptors on platelets of uremic patients is correlated with the content of GPIIb and plasma level of creatinine

3 January 2024

14

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors

3 January 2024

15

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Platelet Function in Renal Failure

3 January 2024

18

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Effect of nitric oxide synthase inhibition on bleeding time in humans.

3 January 2024

19

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension

3 January 2024

20

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Physiology and pathophysiology of nitric oxide in chronic renal disease.

3 January 2024

21

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Effect of chronic renal failure on nitric oxide metabolism.

3 January 2024

22

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Enhanced platelet aggregation in chronic renal failure patients receiving hemodialysis treatment

3 January 2024

23

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Haemodialysis and platelet activation

3 January 2024

24

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Platelet function in patients on maintenance hemodialysis: depressed or enhanced?

3 January 2024

27

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Enhanced in vitro platelet aggregation in hemodialysis patients

3 January 2024

28

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Impaired endothelium-dependent vasodilatation in renal failure in humans

3 January 2024

30

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Insulin levels and fibrinolytic activity in patients with end-stage renal disease

3 January 2024

32

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients

3 January 2024

33

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia

3 January 2024

34

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Vasodilation to acetylcholine in primary and secondary forms of human hypertension

3 January 2024

37

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure

3 January 2024

40

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

3 January 2024

41

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Plasma parameters of the prothrombotic state in chronic uremia

3 January 2024

42

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Plasma von Willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing regular hemodialysis therapy

3 January 2024

43

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Oxidative stress in haemodialysis

3 January 2024

45

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure

3 January 2024

46

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Lipid peroxidation on dialysis membranes

3 January 2024

47

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis

3 January 2024

48

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy

3 January 2024

50

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors

3 January 2024

51

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease

3 January 2024

52

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial

3 January 2024

53

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance

3 January 2024

55

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease.

3 January 2024

56

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients

3 January 2024

57

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis

3 January 2024

58

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Enhanced fibrinolysis caused by tissue plasminogen activator release in hemodialysis

3 January 2024

59

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

TAT and PAP in hemodialysis patients: two cats in a bag?

3 January 2024

60

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Protein C assays in uremia

3 January 2024

62

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Further investigations of the defective protein C in hemodialysis, hemofiltration and continuous ambulatory peritoneal dialysis

3 January 2024

63

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Protein C in renal allotransplantation during the perioperative period

3 January 2024

64

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Effect of hemodialysis on protein C levels

3 January 2024

65

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis.

3 January 2024

66

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Acquired type II protein C deficiency in a long-term hemodialysis patient

3 January 2024

67

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Protein C, protein S, and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis and hemodialysis

3 January 2024

68

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

URAEMIC BLEEDING: ROLE OF ANAEMIA AND BENEFICIAL EFFECT OF RED CELL TRANSFUSIONS

3 January 2024

71

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Recombinant human erythropoietin treatment improves platelet function in uremic patients

3 January 2024

73

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation

3 January 2024

75

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin.

3 January 2024

76

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells

3 January 2024

78

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Effect of recombinant human erythropoietin on vascular access

3 January 2024

80

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

3 January 2024

81

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

3 January 2024

84

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis

3 January 2024

85

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients

3 January 2024

87

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis

3 January 2024

88

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

3 January 2024

89

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Erythropoietin for end-stage renal disease

3 January 2024

90

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.

3 January 2024

92

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Examination Survey

3 January 2024

93

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?

3 January 2024

94

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.

3 January 2024

95

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes

3 January 2024

96

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients

3 January 2024

97

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients.

3 January 2024

99

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

C-reactive protein as an outcome predictor for maintenance hemodialysis patients.

3 January 2024

102

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients

3 January 2024

104

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Inflammation enhances cardiovascular risk and mortality in hemodialysis patients

3 January 2024

105

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Canadian Hemodialysis Morbidity Study

3 January 2024

106

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Pulmonary embolism in end stage renal disease

3 January 2024

110

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Prevalence of preterminal pulmonary thromboembolism among patients on maintenance hemodialysis treatment before and after introduction of recombinant erythropoietin.

3 January 2024

111

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Venous thromboembolism in end-stage renal disease

3 January 2024

112

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Deep venous thrombosis in haemodialysis patients - a pointer to the presence of malignancy?

3 January 2024

113

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

3 January 2024

114

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Chronic dialysis patients have high risk for pulmonary embolism.

3 January 2024

115

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Vascular access for hemodialysis

3 January 2024

116

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment

3 January 2024

117

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts

3 January 2024

118

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Cell proliferation in human arteriovenous fistulas used for hemodialysis

3 January 2024

119

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis

3 January 2024

121

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients

3 January 2024

122

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Natural history of arteriovenous grafts in hemodialysis patients

3 January 2024

125

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

A practical approach to vascular access for hemodialysis and predictors of success.

3 January 2024

126

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Recurrent Septic Pulmonary Embolization Complicating Maintenance Hemodialysis

3 January 2024

128

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Septicaemia and pulmonary embolism complicating use of arteriovenous fistula in maintenance haemodialysis

3 January 2024

129

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey

3 January 2024

133

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Complications of percutaneous femoral vein catheterizations for hemodialysis

3 January 2024

134

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Bacteremic infection in hemodialysis

3 January 2024

135

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Septicaemia and pulmonary embolism complicating maintenance haemodialysis

3 January 2024

136

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Ventilation-perfusion scintigraphic evaluation of pulmonary clot burden after percutaneous thrombolysis of clotted hemodialysis access grafts.

3 January 2024

138

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Pulmonary embolism following hemodialysis access thrombolysis/thrombectomy

3 January 2024

140

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Atrial thrombus and central venous dialysis catheters

3 January 2024

141

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

A retrospective experience of right atrial and superior vena caval thrombi diagnosed by transesophageal echocardiography

3 January 2024

142

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Elevated plasma free apo(a) levels in hemodialysis patients

3 January 2024

145

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.

3 January 2024

146

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients

3 January 2024

147

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis

3 January 2024

148

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

3 January 2024

149

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

3 January 2024

Heparin

150

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Heparin-induced thrombocytopenia in hemodialysis patients

3 January 2024

151

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients

3 January 2024

152

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis

3 January 2024

153

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis

3 January 2024

154

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Heparin-induced thrombocytopenia (HIT) and thrombosis in a haemodialysis-dependent patient with systemic vasculitis

3 January 2024

155

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Clotting by heparin of hemoaccess for hemodialysis in an end-stage renal disease patient

3 January 2024

157

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Effect of aspirin on heparin-induced thrombocytopenia (HIT) in a patient requiring hemodialysis

3 January 2024

158

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Hemodialysis without anticoagulants in patients with high bleeding risk

3 January 2024

159

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Hemodialysis without anticoagulation

3 January 2024

161

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Hemodialysis without anticoagulation. One-year prospective trial in hospitalized patients at risk for bleeding

3 January 2024

162

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Safety of regional citrate hemodialysis in acute renal failure

3 January 2024

163

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Regional citrate anticoagulation for hemodialysis following cardiovascular surgery

3 January 2024

164

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A

3 January 2024

165

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Regional anticoagulation: hemodialysis with hypertonic trisodium citrate

3 January 2024

166

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Long-term comparisons of citrate and heparin as anticoagulants for hemodialysis

3 January 2024

167

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban

3 January 2024

168

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Effect of a new anticoagulant (MD 805) on platelet activation in the hemodialysis circuit

3 January 2024

169

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Anticoagulation with r-hirudin in a patient with acute renal failure and heparin-induced thrombocytopenia

3 January 2024

171

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

A case review: anticoagulation in hemodialysis patients with heparin-induced thrombocytopenia

3 January 2024

172

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Acute renal artery and vein thrombosis after renal transplant, associated with a short partial thromboplastin time and factor V Leiden mutation

3 January 2024

173

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Heterozygous prothrombin gene mutation: a new risk factor for early renal allograft thrombosis

3 January 2024

174

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Vascular Complications in 155 Consecutive Kidney Transplantations

3 January 2024

175

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Factor V Leiden: a risk factor for renal vein thrombosis in renal transplantation

3 January 2024

176

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

The factor V Leiden mutation and risk of renal vein thrombosis in patients with nephrotic syndrome

3 January 2024

177

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Successful treatment of acute transplant renal vein thrombosis with selective streptokinase infusion

3 January 2024

178

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Dialysis modality and the risk of allograft thrombosis in adult renal transplant recipients

3 January 2024

180

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Allograft renal vein thrombosis

3 January 2024

182

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Deep venous thrombosis after renal transplantation

3 January 2024

184

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Postoperative deep venous thrombosis after renal transplantation. Effects of cyclosporine

3 January 2024

185

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Cyclosporine nephrotoxicity

3 January 2024

186

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Cyclosporine-associated thrombotic microangiopathy in renal allografts

3 January 2024

188

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

FK506-associated thrombotic microangiopathy: report of two cases and review of the literature

3 January 2024

189

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Induction of thromboses within renal grafts by high-dose prophylactic OKT3

3 January 2024

190

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Procoagulant effect of the OKT3 monoclonal antibody: involvement of tumor necrosis factor

3 January 2024

191

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders

3 January 2024

192

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency

3 January 2024

193

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Treatment of failed native arteriovenous fistulae for hemodialysis by interventional radiology

3 January 2024

194

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Salvage of occluded autologous arteriovenous fistulae

3 January 2024

195

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Prevention of hemodialysis fistula thrombosis. Early detection of venous stenoses

3 January 2024

197

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Prolongation of hemodialysis access survival with elective revision

3 January 2024

198

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis

3 January 2024

199

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Antithrombotic agents and the prevention of access thrombosis

3 January 2024

200

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Pharmacologic intervention to prevent hemodialysis vascular access thrombosis

3 January 2024

201

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Medical and revascularization management in acute coronary syndrome in renal patients

3 January 2024

203

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: a case-control study using quantitative coronary angiography.

3 January 2024

204

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Short- and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients

3 January 2024

205

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Complications and long-term outcome after percutaneous coronary angioplasty in chronic hemodialysis patients

3 January 2024

206

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Hemostasis, platelet function and serotonin in acute and chronic renal failure

3 January 2024

208

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Adenylate cyclase activity and cAMP content of human platelets in uraemia

3 January 2024

209

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Elevated thrombocyte calcium content in uremia and its correction by 1 alpha(OH) vitamin D treatment

3 January 2024

210

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Defective platelet aggregation in uremia is transiently worsened by hemodialysis

3 January 2024

213

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

The role of red cells in haemostasis: the relation between haematocrit, bleeding time and platelet adhesiveness

3 January 2024

214

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Enhanced prostacyclin availability of blood vessels in uraemic humans and rats

3 January 2024

215

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Prostacyclin-like activity and bleeding in renal failure

3 January 2024

216

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Comprehensive study of haemostasis in chronic uraemia

3 January 2024

217

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation, and factor VII genotype

3 January 2024

218

1 reference

https://api.crossref.org/works/10.1046/J.1525-139X.2003.16048.X

3 January 2024

Identifiers

1 reference

26 July 2017

1 reference